Related Experiment Video
Updated: Mar 17, 2026

In Vivo Imaging and Quantitation of the Host Angiogenic Response in Zebrafish Tumor Xenografts
Published on: August 14, 2019
EphrinB2 repression through ZEB2 mediates tumour invasion and anti-angiogenic resistance
C Depner1, H Zum Buttel2, N Böğürcü1
1Institute of Neuropathology, University of Giessen, Arndtstr. 16, D-35392 Giessen, Germany.
Abstract:
Diffuse invasion of the surrounding brain parenchyma is a major obstacle in the treatment of gliomas with various therapeutics, including anti-angiogenic agents. Here we identify the epi-/genetic and microenvironmental downregulation of ephrinB2 as a crucial step that promotes tumour invasion by abrogation of repulsive signals. We demonstrate that ephrinB2 is downregulated in human gliomas as a consequence of promoter hypermethylation and gene deletion. Consistently, genetic deletion of ephrinB2 in a murine high-grade glioma model increases invasion. Importantly, ephrinB2 gene silencing is complemented by a hypoxia-induced transcriptional repression. Mechanistically, hypoxia-inducible factor (HIF)-1α induces the EMT repressor ZEB2, which directly downregulates ephrinB2 through promoter binding to enhance tumour invasiveness. This mechanism is activated following anti-angiogenic treatment of gliomas and is efficiently blocked by disrupting ZEB2 activity. Taken together, our results identify ZEB2 as an attractive therapeutic target to inhibit tumour invasion and counteract tumour resistance mechanisms induced by anti-angiogenic treatment strategies.
Insights
Glioma invasion is promoted by downregulation of ephrinB2, a gene silenced by epigenetic changes and hypoxia-induced ZEB2. Targeting ZEB2 can inhibit glioma invasion and overcome resistance to anti-angiogenic therapies.
Area of Science:
- Neuro-oncology
- Molecular biology
- Cancer genetics
Background:
- Diffuse invasion of brain parenchyma is a significant challenge in glioma treatment.
- Anti-angiogenic agents face limitations due to tumor invasion and resistance mechanisms.
Purpose of the Study:
- To identify key molecular mechanisms driving glioma invasion.
- To investigate the role of ephrinB2 in glioma progression and therapeutic resistance.
Main Methods:
- Analysis of ephrinB2 expression in human gliomas.
- Genetic manipulation of ephrinB2 in a murine glioma model.
- Investigation of hypoxia-inducible factor (HIF)-1α and ZEB2 involvement.
- Assessment of ZEB2 inhibition in blocking tumor invasion.
Main Results:
- EphrinB2 is downregulated in human gliomas via promoter hypermethylation and gene deletion.
- Genetic deletion of ephrinB2 exacerbates invasion in a mouse glioma model.
- Hypoxia-induced HIF-1α upregulates ZEB2, which represses ephrinB2 expression, enhancing invasiveness.
- This mechanism is activated by anti-angiogenic treatment and blocked by ZEB2 inhibition.
Conclusions:
- EphrinB2 downregulation is a critical step promoting glioma invasion.
- ZEB2 acts as a key mediator of hypoxia-induced invasion and therapeutic resistance.
- Targeting ZEB2 presents a promising strategy to inhibit glioma invasion and improve treatment outcomes.
More Related Videos
Related Concept Videos
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
Regulation of Angiogenesis and Blood Supply
Mitogens and the Cell Cycle
The Tumor Microenvironment

